Natera Reports Q3 2026 Revenue Growth of 34% and Raises Full-Year Guidance
Natera (NTRA) delivered strong third-quarter 2026 financial results, reporting total revenues of $794.0 million, a 34.1% increase year-over-year. This growth was primarily driven by higher test volumes and improved average selling prices across its oncology and organ health segments. The company's clinical MRD units saw significant expansion, growing 56% year-over-year to 316,000 units. Reflecting this momentum, Natera raised its full-year 2026 revenue guidance by $140 million at the midpoint, now projecting between $3.005 billion and $3.035 billion. While the company reported a net loss of $59.9 million, this represents a narrowing of losses compared to the prior year period. The firm maintains a robust cash position of over $1 billion as it continues to invest heavily in R&D and clinical trials for early cancer detection.
Topics: clinical testing volume guidance raise net loss narrowing revenue growth